Notice of Allowance for US patent on Sofdra drug substance
Open PDF
| Stock | Botanix Pharmaceuticals Ltd (BOT.ASX) |
|---|---|
| Release Time | 13 Jul 2026, 9:13 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Botanix Pharmaceuticals Receives Notice of Allowance for US Patent
Key Points
- Botanix Pharmaceuticals receives Notice of Allowance for US patent
- Patent covers Sofdra drug substance technology
- Expected to extend patent protection until May 2040
- Strengthens intellectual property for Sofdra in the US
Full Summary
Botanix Pharmaceuticals Limited, a commercial dermatology company, announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a US patent application covering the drug substance for Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis. The allowed claims pertain to the proprietary aspects of sofpironium drug substance technology used in the commercial manufacture of Sofdra. This patent, once issued, will provide additional intellectual property protection for Sofdra in the United States, extending protection until May 2040.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In